Prague Med. Rep. 2023, 124, 5-15

Janus Kinase Inhibitors in the Treatment of Alopecia Areata

Athanasios J. Stefanis

Department of Dermatovenerology, Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic

Received September 11, 2022
Accepted January 13, 2023

Alopecia areata is a disease of autoimmune origin which causes non scarring hair loss. The extent of alopecia varies from a small patch to complete scalp and body hair loss, which can have huge psychosocial impact for those affected. Treatment modalities which have been used so far included nonspecific immunosuppressive medications, such as corticosteroids, cyclosporine, and methotrexate, or topical immunomodulators, such as diphencyprone, dithranol, and squaric acid dibutylester. The recognition of the importance of Janus kinase pathway in alopecia areata pathogenesis enabled more specific approaches in treatment. Positive outcomes of Janus kinase inhibitors in several trials granted approval for baricitinib which became the first on-label treatment for alopecia areata. The aim of this review is to summarize the role, efficacy and safety of several Janus kinase inhibitors in alopecia areata.


39 live references